HC Wainwright Has Bearish Forecast for BHST FY2026 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Analysts at HC Wainwright decreased their FY2026 EPS estimates for BioHarvest Sciences in a research note issued to investors on Monday, November 17th. HC Wainwright analyst A. Dayal now anticipates that the company will earn $0.00 per share for the year, down from their previous forecast of $0.04. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ FY2027 earnings at $0.22 EPS, FY2028 earnings at $0.55 EPS and FY2029 earnings at $1.00 EPS.

BioHarvest Sciences (NASDAQ:BHST) last posted its earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. The business had revenue of $9.07 million for the quarter, compared to analyst estimates of $9.11 million.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of BioHarvest Sciences in a report on Wednesday, October 8th. Wall Street Zen raised shares of BioHarvest Sciences to a “hold” rating in a research report on Saturday, October 18th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.67.

BioHarvest Sciences Trading Down 0.8%

NASDAQ:BHST opened at $6.61 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.35 and a quick ratio of 1.02. BioHarvest Sciences has a 12 month low of $4.72 and a 12 month high of $12.80. The firm has a market capitalization of $108.54 million, a PE ratio of -9.72 and a beta of 0.76. The business’s 50-day moving average is $9.66 and its two-hundred day moving average is $8.14.

Institutional Investors Weigh In On BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC grew its holdings in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) by 7.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,391 shares of the company’s stock after buying an additional 3,120 shares during the quarter. True North Advisors LLC owned 0.27% of BioHarvest Sciences worth $275,000 as of its most recent SEC filing.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.